Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harte Hanks (HHS) EBITDA Margin (2016 - 2025)

Harte Hanks has reported EBITDA Margin over the past 16 years, most recently at 1.78% for Q4 2025.

  • Quarterly EBITDA Margin rose 98.0% to 1.78% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.37% through Dec 2025, down 148.0% year-over-year, with the annual reading at 1.37% for FY2025, 148.0% down from the prior year.
  • EBITDA Margin was 1.78% for Q4 2025 at Harte Hanks, up from 6.31% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 55.94% in Q4 2022 and troughed at 6.31% in Q3 2025.
  • The 5-year median for EBITDA Margin is 1.49% (2023), against an average of 6.59%.
  • Year-over-year, EBITDA Margin soared 3553bps in 2021 and then tumbled -5762bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 25.57% in 2021, then surged by 119bps to 55.94% in 2022, then tumbled by -103bps to 1.68% in 2023, then soared by 148bps to 0.8% in 2024, then skyrocketed by 122bps to 1.78% in 2025.
  • Per Business Quant, the three most recent readings for HHS's EBITDA Margin are 1.78% (Q4 2025), 6.31% (Q3 2025), and 0.56% (Q2 2025).